Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000235077 | SCV003439242 | uncertain significance | Tay-Sachs disease, variant AB | 2024-05-20 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 55 of the GM2A protein (p.Pro55Leu). This variant is present in population databases (rs730882196, gnomAD no frequency). This missense change has been observed in individual(s) with features of GM2-gangliosidosis (PMID: 25558065, 26203402, 28417072, 33456446). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 183275). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Studies have shown that this missense change alters GM2A gene expression (PMID: 28417072). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Genomic Medicine Center of Excellence, |
RCV000235077 | SCV004805033 | uncertain significance | Tay-Sachs disease, variant AB | 2024-03-17 | criteria provided, single submitter | research | |
Genomic Medicine Center of Excellence, |
RCV000162097 | SCV000196382 | likely pathogenic | Neurodegenerative illness progressing to crippling dystonia and death with relentless cerebral atrophy | 2014-12-01 | no assertion criteria provided | research | |
OMIM | RCV000235077 | SCV000292429 | pathogenic | Tay-Sachs disease, variant AB | 2016-10-21 | no assertion criteria provided | literature only | |
Biochemical Molecular Genetic Laboratory, |
RCV000235077 | SCV001133056 | likely pathogenic | Tay-Sachs disease, variant AB | 2019-09-26 | no assertion criteria provided | clinical testing |